LeMaitre Vascular (NASDAQ:LMAT) Releases FY24 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $1.73-1.84 for the period, compared to the consensus EPS estimate of $1.65. The company issued revenue guidance of $212.7-217.3 million, compared to the consensus revenue estimate of $211.69 million. LeMaitre Vascular also updated its Q2 guidance to $0.45-0.50 EPS.

LeMaitre Vascular Stock Down 0.0 %

NASDAQ LMAT traded down $0.01 on Thursday, hitting $66.77. 176,660 shares of the stock were exchanged, compared to its average volume of 114,195. LeMaitre Vascular has a fifty-two week low of $44.27 and a fifty-two week high of $74.64. The company has a market cap of $1.50 billion, a PE ratio of 49.28, a PEG ratio of 2.79 and a beta of 0.88. The company has a 50-day moving average price of $65.56 and a 200-day moving average price of $58.47.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The business had revenue of $48.90 million during the quarter, compared to the consensus estimate of $49.01 million. During the same quarter last year, the firm posted $0.25 EPS. The business’s revenue was up 19.3% compared to the same quarter last year. As a group, equities research analysts predict that LeMaitre Vascular will post 1.66 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, March 14th were paid a dividend of $0.16 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date was Wednesday, March 13th. LeMaitre Vascular’s payout ratio is currently 47.76%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LMAT shares. Barrington Research upped their target price on LeMaitre Vascular from $66.00 to $69.00 and gave the stock an outperform rating in a research report on Wednesday, February 28th. Stifel Nicolaus upgraded LeMaitre Vascular from a hold rating to a buy rating and boosted their target price for the company from $59.00 to $75.00 in a research note on Friday, April 26th. KeyCorp started coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They set a sector weight rating for the company. Finally, StockNews.com lowered LeMaitre Vascular from a buy rating to a hold rating in a report on Tuesday, April 16th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, LeMaitre Vascular currently has a consensus rating of Moderate Buy and an average price target of $69.33.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 36,600 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the completion of the transaction, the chief executive officer now owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO George W. Lemaitre sold 36,600 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the transaction, the chief executive officer now owns 2,187,526 shares of the company’s stock, valued at $148,817,393.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the completion of the transaction, the chief financial officer now owns 6,452 shares in the company, valued at $450,091.52. The disclosure for this sale can be found here. Insiders sold 114,036 shares of company stock valued at $7,873,749 over the last 90 days. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.